Patents by Inventor Rudolf Hauptmann
Rudolf Hauptmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020155112Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: July 3, 2001Publication date: October 24, 2002Applicant: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6440693Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 2002Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Publication number: 20020090676Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: ApplicationFiled: July 3, 2001Publication date: July 11, 2002Applicant: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6417158Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: July 9, 2002Assignee: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6294352Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequence can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: February 1, 1995Date of Patent: September 25, 2001Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6271346Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: August 7, 2001Assignee: Amgen Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 6221675Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF is receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: April 24, 2001Assignee: Amgen, Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 5843791Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.Type: GrantFiled: June 7, 1995Date of Patent: December 1, 1998Assignee: Amgen Boulder Inc.Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
-
Patent number: 5837842Abstract: This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.Type: GrantFiled: January 23, 1995Date of Patent: November 17, 1998Assignee: Boehringer Ingelheim International GmbHInventors: Rudolf Hauptmann, Ingrid Maurer-Fogy, Gerhard Bodo, Peter Swetly, Christian Stratowa, Edgar Falkner, Gunther Adolf, Christiaan Maria Peter Reutelingsperger
-
Patent number: 5798228Abstract: This invention relates to a process for preparing recombinant horse and dog interferons and the interferons themselves.Type: GrantFiled: February 24, 1997Date of Patent: August 25, 1998Assignee: Boehringer Ingelheim International GmbHInventors: Adolf Himmler, Rudolf Hauptmann, Norbert Hauel, Gunther Adolf, Peter Swetly
-
Patent number: 5710027Abstract: Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.Type: GrantFiled: May 26, 1994Date of Patent: January 20, 1998Assignee: Boehringer Ingelheim International GmbHInventors: Rudolf Hauptmann, Edgar Falkner, Gerhard Bodo, Tilman Voss, Ingrid Maurer-Fogy
-
Patent number: 5618712Abstract: This invention relates to a process for preparing human lysozyme and the human lysozyme protein itself.Type: GrantFiled: April 4, 1994Date of Patent: April 8, 1997Assignee: Boehringer Ingelheim Zentrale GmbHInventors: Andrzej Sledziewski, Ewa Chlebowicz-Sledziewska, Peter Swetly, Gunther Adolf, Rudolf Hauptmann, Maria J. Castanon, Walter Spevak
-
Patent number: 5605688Abstract: This invention relates to a process for preparing recombinant horse and dog interferons and the interferons themselves.Type: GrantFiled: September 8, 1994Date of Patent: February 25, 1997Assignee: Boehringer Ingelheim International GmbHInventors: Adolf Himmler, Rudolf Hauptmann, Norbert Hauel, Gunther Adolf, Peter Swetly
-
Patent number: 5602010Abstract: The present invention relates to a process for preparing horse interferon-gamma (equine interferon gamma, EqIFN-.gamma., DNA sequences which encode this polypeptide, suitable vectors and host organisms containing these DNA sequences and the EqIFN-.gamma. itself. The invention further relates to partial DNA sequences which encode polypeptides which differ structurally from the natural EqIFN-.gamma. polypeptide. The use of the proteins is also described.Type: GrantFiled: June 17, 1994Date of Patent: February 11, 1997Assignee: Boehringer Ingelheim International GmbHInventors: Rudolf Hauptmann, Adolf Himmler, Peter Swetly
-
Patent number: 5589371Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: March 30, 1995Date of Patent: December 31, 1996Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 5436162Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: September 15, 1992Date of Patent: July 25, 1995Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 5260204Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: September 15, 1992Date of Patent: November 9, 1993Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 5240847Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.Type: GrantFiled: March 11, 1988Date of Patent: August 31, 1993Assignee: Boehringer Ingelheim International GmbHInventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
-
Patent number: 4917887Abstract: This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,new monoclonal antibodies and their use in purifying .alpha. and omega-interferons, the hybrid cell lines which secrete them and processes for preparing them,a new process for purifying .alpha. and omega-interferons by means of a new antibody affinity column containing the above-mentioned new monoclonal antibodies, and processes for the preparation thereof,new hybrid plasmids for improving the expression of omega-interferons and new intermediate plasmids for preparing the new plasmids and processes for the preparation thereof.Type: GrantFiled: March 9, 1987Date of Patent: April 17, 1990Assignee: Boehringer Ingelheim International GmbHInventors: Rudolf Hauptmann, Peter Swetly, Peter Meindl, Gunther Adolf, Edgar Falkner, Gerhard Bodo, Ingrid Maurer-Fogy
-
Patent number: 4730189Abstract: A pulse Doppler radar system with variable pulse repetition frequency has a coherent integrator to which the reflected pulses are supplied in order to avoid deterioration of the indication of a moving target given over-the-horizon reception. The coherent integrator subjects the reflected pulses to a simplified vectorial addition by the use of a number of filters. A precondition for the modified coherent integration is a staggering of the pulse repetition periods such that their sums formed over successive pulse repetition periods are constant, and a phase reference for the signal amplitudes is obtained such that the phase difference is equal to zero after every second pulse repetition.Type: GrantFiled: May 24, 1984Date of Patent: March 8, 1988Assignee: Siemens AktiengesellschaftInventors: Harald Siegel, Rudolf Hauptmann